Small Business Innovation Research Grants: Difference between revisions

no edit summary
No edit summary
No edit summary
Line 12: Line 12:
|Historic=false
|Historic=false
}}
}}
The '''Small Business Innovation Research (SBIR) Grants''', established in 1983 under the Small Business Innovation Development Act of 1982, are administered by multiple federal agencies, including the National Institutes of Health (NIH) within the Department of Health and Human Services, to provide competitive grants to small businesses (fewer than 500 employees), allocating over $50 billion since inception to support approximately 5,000 projects annually by 2025. Initially funded with $45 million across all participating agencies, it has grown to distribute $1.2 billion in FY 2024 across 5,000 awards at NIH alone, funding innovations like medical devices, biotechnology, and health IT for small businesses nationwide.<ref>{{cite web |url=https://sbir.nih.gov |title=SBIR at NIH |publisher=National Institutes of Health}}</ref> Despite its impact, challenges like funding competition and commercialization barriers persist (web ID: 4), but it remains a cornerstone of federal innovation support under HHS and other agencies.
The '''Small Business Innovation Research (SBIR) Grants''', established in 1983 under the Small Business Innovation Development Act of 1982, are administered by multiple federal agencies, including the National Institutes of Health (NIH) within the Department of Health and Human Services, to provide competitive grants to small businesses (fewer than 500 employees), allocating over $50 billion since inception to support approximately 5,000 projects annually by 2025. Initially funded with $45 million across all participating agencies, it has grown to distribute $1.2 billion in FY 2024 across 5,000 awards at NIH alone, funding innovations like medical devices, biotechnology, and health IT for small businesses nationwide.<ref>{{cite web |url=https://sbir.nih.gov |title=SBIR at NIH |publisher=National Institutes of Health}}</ref> Despite its impact, challenges like funding competition and commercialization barriers persist (web ID: 4), but it remains a cornerstone of federal innovation support under HHS and other agencies.